Menu Search
Equities

Conavi Medical Corp

YU1:DEU

Conavi Medical Corp

Actions
  • Price (EUR)0.596
  • Today's Change-0.009 / -1.49%
  • Shares traded0.00
  • 1 Year change-62.16%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Conavi Medical Corp., formerly Titan Medical Inc., is a Canada-based company. The Company is focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. The Novasight Hybrid System is intended for intravascular imaging of coronary arteries and is indicated in patients who are candidates for transluminal interventional procedures. Its Novasight Hybrid System combines both intravascular ultrasound (IVUS) and optical coherence tomography (OCT) to enable simultaneous and co-registered imaging of coronary arteries. Hybrid IVUS and OCT imaging provides additional information over single modality imaging in complex lesions. The versatility of hybrid imaging is useful for a variety of complex percutaneous coronary intervention (PCIs), including situations where the customer may want to image large ostial lesions with IVUS but also use OCT for diseased distal lesions and/or stent assessment.

  • Revenue in CAD (TTM)1.33m
  • Net income in CAD-7.06m
  • Incorporated2008
  • Employees4.00
  • Location
    Conavi Medical Corp76 Berkeley StreetTORONTO M5A 2W7CanadaCAN
  • Phone+1 (416) 548-7522
  • Fax+1 (416) 548-7522
  • Websitehttps://titanmedicalinc.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		CNVI:CVE since
announced		Transaction
value
Conavi Medical IncDeal completed18 Mar 202418 Mar 2024Deal completed-59.11%--
Data delayed at least 15 minutes, as of Nov 13 2024 16:23 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.